Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Paeds Vivasneurology-neurodisability-and-neuromuscular

Paeds Vivas · neurology-neurodisability-and-neuromuscular

Neurodegenerative and leukodystrophy disorders — branching viva

Branching viva on neurodegenerative and leukodystrophy disorders: reading the contrasted brain MRI to name the mechanism group, recognising the transplant emergency of cerebral X-linked adrenoleukodystrophy, deploying a magnetic-resonance-imaging-led tiered workup, matching disease-modifying therapy to the named disorder, and understanding that the treatable leukodystrophies are treated before symptoms begin through newborn screening.

branching clinical structured oral3 min readVerification in progress

Target exams

RACP DCEMRCPCH ClinicalRCPSC Pediatrics
On this page
Study tools

Target exams

RACP DCEMRCPCH ClinicalRCPSC Pediatrics
Prompt
Outpatient clinic: a seven-year-old boy with two months of school decline and a parieto-occipital white-matter lesion on an unenhanced MRI. The examiner asks: what is the mechanism-based classification, what addition to the scan settles the transplant decision, and what is your tiered workup - then branches to a two-year-old with a tigrid pattern and progressive spastic ataxia, and finally to a neonate identified by newborn bloodspot screening positive for X-linked adrenoleukodystrophy.

Opening branch — the boy with the parieto-occipital lesion

A previously well seven-year-old presents with two months of school decline, difficulty following the ball at sport, and intermittent vomiting, with an unenhanced brain MRI showing symmetric parieto-occipital white-matter change. The candidate must first recognise this as a likely cerebral X-linked adrenoleukodystrophy and name the mechanism-based classification - lysosomal and dysmyelinating, peroxisomal and inflammatory, hypomyelinating, astrocytopathic and interferonopathic - placing this disorder in the peroxisomal and inflammatory group driven by very-long-chain fatty acid accumulation and CD8 T-cell-mediated inflammation. [1] [2]

The examiner probes the management decision. The candidate states that the single addition that settles the transplant question is gadolinium contrast, because the enhancing leading edge of the inflammatory phase confirms active cerebral disease and is missed on the unenhanced scan, and that the Loes score alongside the neurological examination stages the disease. The teaching point is that allogeneic haematopoietic stem cell transplant halts the inflammation only when the burden is still low and the examination preserved, so the case is a transplant-pace emergency referred the same day. [2]

Paediatrics Fellowship Pro

Continue reading

You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship library.

Sign in to continueSee pricing
References5ShowHide
  1. [1]Parikh S, Bernard G, Leventer RJ, et al. A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephelopathies. Mol Genet Metab, 2015.PMID 25655951
  2. [2]Engelen M, van Ballegoij WJC, Mallack EJ, et al. International Recommendations for the Diagnosis and Management of Patients With Adrenoleukodystrophy: A Consensus-Based Approach. Neurology, 2022.PMID 36175155
  3. [3]Mallack EJ, Turk BR, Yan H, et al. MRI surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: Meta-analysis and consensus guidelines. J Inherit Metab Dis, 2021.PMID 33373467
  4. [4]Sessa M, Lorioli L, Fumagalli F, et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial and an extension study. Lancet, 2016.PMID 27289174
  5. [5]van Voorst RJ, Schoenmakers DH, Bonkowsky JL, et al. Consensus-Based Expert Recommendations for Diagnosis and Clinical Management of Vanishing White Matter. Neurology, 2025.PMID 41232062
Paediatrics Fellowship Pro

$29/ monthor $279 / year

The complete Paediatrics Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousNeural tube defects and spinal dysraphism: Vivaneurology-neurodisability-and-neuromuscularNextNeurogenetic conditions and precision diagnosis: Vivaneurology-neurodisability-and-neuromuscular